NodThera strengthens C-level team to advance fight against inflammatory disease
Cambridge biotech NodThera, which raised a stunning $55 million Series B last summer, has made two high-level hires as it advances a new class of medicines to fight chronic inflammation.
Dr Donald Johns becomes chief medical officer and Katina Dorton chief financial officer.
Dr Johns is an accomplished drug development leader and board-certified clinical neurologist who previously served as CMO and executive VP of Medical and Scientific Affairs at Syntimmune, prior to the company’s acquisition by Alexion Pharmaceuticals.
Katrina Dorton is a recognised and internationally experienced financial executive, corporate director and public company CFO. Her industry expertise includes roles in healthcare, life sciences and investment banking, including experiences at Repare Therapeutics and AVROBIO, Inc.
NodThera is advancing a portfolio of potent and selective inhibitors of the NLRP3 inflammasome that reduce both IL-1β and IL-18, pro-inflammatory cytokines which are known to play a role in chronic inflammation underlying a wide range of diseases. The pipeline includes brain penetrant NLRP3 inhibitors for central nervous system indications.
Chesterford Research Park based NodThera was founded in 2016 by Epidarex Capital and further financed by 5AM Ventures, Cowen Healthcare Investments, F-Prime Capital, Novo Holdings, Sanofi Ventures and Sofinnova Partners. NodThera has additional offices in Seattle and Boston, US